MarketCap
Facebook
X
TelegramАптеки 36.6 Income Statement 2004-2025 | APTK
Annual Income Statement Аптеки 36.6
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue |
59 B | 44.1 B | 39.3 B | 46 B | 44.7 B | 48.3 B | 45.9 B | 31.9 B | 19.1 B | 11.9 B | 20.9 B | 21.6 B | 20.4 B | 21.1 B | 30.7 B | 20.8 B | 14.4 B | 8.64 B | 6.05 B |
Cost Of Revenue |
38.9 B | 29.1 B | 25.7 B | 32.9 B | 38.8 B | 37.4 B | 36.2 B | 23.1 B | 13.6 B | 8.92 B | 13.4 B | 11.9 B | 12 B | 12.8 B | 20.2 B | 14.6 B | 9.39 B | 5.3 B | 3.72 B |
Gross Profit |
20.2 B | 15 B | 13.6 B | 13.1 B | 5.84 B | 10.8 B | 9.72 B | 8.79 B | 5.5 B | 2.99 B | 7.56 B | 9.67 B | 8.41 B | 8.3 B | 10.6 B | 6.19 B | 4.98 B | 3.33 B | 2.33 B |
Gross Profit Ratio |
0.34 | 0.34 | 0.35 | 0.28 | 0.13 | 0.22 | 0.21 | 0.28 | 0.29 | 0.25 | 0.36 | 0.45 | 0.41 | 0.39 | 0.34 | 0.3 | 0.35 | 0.39 | 0.38 |
General and Administrative Expenses |
1.1 B | 14.2 B | 226 M | 472 M | 499 M | 312 M | 123 M | 153 M | 126 M | 314 M | 69 M | 7.89 B | 7.15 B | 7.36 B | 10.3 B | 7.48 B | - | - | - |
Selling And Marketing Expenses |
368 M | 213 M | 645 M | 1.04 B | 1.16 B | 780 M | 924 M | 371 M | 479 M | 117 M | 1.42 B | - | - | - | - | - | - | - | - |
Selling General And Administrative Expenses |
1.47 B | 14.5 B | 871 M | 1.52 B | 9.94 B | 14.6 B | 14.9 B | 9.11 B | 605 M | 431 M | 1.49 B | 7.89 B | 7.15 B | 7.36 B | 10.3 B | 7.48 B | 4.64 B | 2.91 B | 2.01 B |
Other Expenses |
18.7 B | - | 11.7 B | 12.3 B | 338 M | -9 M | -12 M | -62 M | 5.26 B | 10.4 B | 64 M | 5 M | 15.2 M | 483 M | -30.1 M | -87.2 M | - | - | - |
Operating Expenses |
20.2 B | 14.5 B | 12.5 B | 13.8 B | 9.94 B | 14.6 B | 14.9 B | 9.17 B | 5.86 B | 10.8 B | 6.93 B | 7.89 B | 7.15 B | 7.36 B | 10.3 B | 7.54 B | 4.64 B | 2.91 B | 2.01 B |
Cost And Expenses |
59 B | 43.6 B | 38.2 B | 46.7 B | 48.8 B | 52 B | 51.1 B | 32.3 B | 19.4 B | 19.7 B | 20.3 B | 19.8 B | 19.1 B | 20.1 B | 30.4 B | 22.1 B | -14 B | -8.21 B | -5.73 B |
Interest Expense |
4.24 B | - | 4.63 B | 5.32 B | 6.4 B | 3.53 B | 2.51 B | 2.03 B | 1.32 B | 1.48 B | 1.48 B | 1.44 B | 1.26 B | 1.17 B | 1.08 B | 943 M | 458 M | 428 M | 230 M |
Depreciation And Amortization |
5.79 B | 1.17 B | 5.02 B | 4.88 B | 5.48 B | 1.5 B | 1.04 B | 424 M | 163 M | 229 M | 404 M | 457 M | 477 M | 481 M | 634 M | 500 M | 351 M | 220 M | 202 M |
EBITDA |
10.4 B | 2.13 B | 9.73 B | 1.22 B | -10 B | -7.42 B | -5.4 B | 41 M | 901 M | -8.18 B | 2.98 B | 1.99 B | 1.74 B | 1.81 B | 475 M | -849 M | 2.21 B | 1.03 B | 544 M |
EBITDA Ratio |
0.18 | 0.05 | 0.16 | 0.09 | 0.03 | -0.05 | -0.09 | 0.0 | 0.05 | -0.69 | 0.05 | 0.13 | 0.09 | 0.07 | 0.02 | -0.04 | 0.15 | 0.12 | 0.09 |
Operating Income |
4.8 B | 504 M | 793 M | -802 M | -4.09 B | -3.79 B | -5.17 B | -383 M | 837 M | -7.81 B | 2.34 B | 1.78 B | 1.26 B | 880 M | -404 M | -1.39 B | 340 M | 426 M | 323 M |
Operating Income Ratio |
0.08 | 0.01 | 0.02 | -0.02 | -0.09 | -0.08 | -0.11 | -0.01 | 0.04 | -0.66 | 0.11 | 0.08 | 0.06 | 0.04 | -0.01 | -0.07 | 0.02 | 0.05 | 0.05 |
Income Before Tax |
411 M | -1.44 B | -643 M | -8.74 B | -22.8 B | -13.1 B | -9.4 B | -1.33 B | -579 M | -9.88 B | 1.09 B | -23 M | -39.1 M | 155 M | -1.77 B | -2.49 B | 1.4 B | 385 M | 113 M |
Income Before Tax Ratio |
0.01 | -32.7 | -0.02 | -0.19 | -0.51 | -0.27 | -0.2 | -0.04 | -0.03 | -0.83 | 0.05 | -0.0 | -0.0 | 0.01 | -0.06 | -0.12 | 0.1 | 0.04 | 0.02 |
Income Tax Expense |
188 M | 492 M | 349 M | 110 M | 220 M | -43 M | -54 M | -170 M | -384 M | 170 M | 223 M | 265 M | 393 M | 129 M | 381 M | 230 M | 266 M | 128 M | 83.3 M |
Net Income Ratio |
0.0 | -0.02 | -0.03 | -0.19 | -0.51 | -0.27 | -0.2 | -0.01 | -0.01 | -0.87 | -0.05 | -0.05 | -0.05 | -0.02 | -0.05 | -0.14 | 0.07 | 0.03 | 0.01 |
Earnings Per Share, EPS |
0.03 | -0.12 | -0.15 | -1.78 | -9.67 | -4.97 | -8.15 | -0.17 | -0.11 | -82.5 | -7.71 | -8.21 | -7.76 | -0.07 | -0.34 | -0.61 | 104 | 25.9 | 3.51 |
EPS Diluted |
0.03 | -0.12 | -0.15 | -1.78 | -9.67 | -4.97 | -8.15 | -0.17 | -0.11 | -82.5 | -7.71 | -8.21 | -7.76 | -0.07 | -0.34 | -0.61 | 104 | 25.9 | 3.51 |
Weighted Average Shares Outstanding |
7.63 B | 7.63 B | 6.81 B | 4.98 B | 2.38 B | 2.64 B | 1.15 B | 1.06 B | 1.09 B | 126 M | 126 M | 126 M | 120 M | 4.88 B | 4.88 B | 4.88 B | 9.05 M | 9.05 M | 9.05 M |
All numbers in RUB currency
Quarterly Income Statement Аптеки 36.6
| 2023-Q2 | 2021-Q4 | 2021-Q2 | 2020-Q4 | 2020-Q2 | 2019-Q4 | 2019-Q2 | 2018-Q4 | 2018-Q2 | 2017-Q4 | 2017-Q2 | 2016-Q4 | 2016-Q2 | 2015-Q4 | 2015-Q2 | 2014-Q2 | 2013-Q4 | 2013-Q2 | 2012-Q4 | 2012-Q2 | 2011-Q4 | 2010-Q4 | 2010-Q2 | 2009-Q4 | 2009-Q2 | 2008-Q4 | 2008-Q2 | 2007-Q4 | 2007-Q2 | 2006-Q4 | 2006-Q2 | 2005-Q4 | 2005-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue |
30.5 B | 23.3 B | 20.8 B | 12.8 B | 26.5 B | 25.2 B | 20.9 B | 22.1 B | 22.6 B | 25.6 B | 22.7 B | 23.2 B | 22.7 B | 15.8 B | 16.1 B | 10.6 B | 5.96 B | 5.96 B | 9.15 B | 11.1 B | 5.9 B | 10.2 B | 10.2 B | 10.5 B | 10.5 B | 15.4 B | 15.4 B | 10.4 B | 10.4 B | 7.19 B | 7.19 B | 4.32 B | 4.32 B |
Cost Of Revenue |
20.4 B | 15.3 B | 13.8 B | 9.8 B | 20.9 B | 20.7 B | 17.4 B | 16.4 B | 17.3 B | 20.1 B | 16 B | 18.8 B | 16.5 B | 12 B | 10.8 B | 7.84 B | 4.46 B | 4.46 B | 5.91 B | 6.39 B | 3.09 B | 5.99 B | 5.99 B | 6.38 B | 6.38 B | 10.1 B | 10.1 B | 7.29 B | 7.29 B | 4.69 B | 4.69 B | 2.65 B | 2.65 B |
Gross Profit |
10.1 B | 7.93 B | 7.03 B | 2.98 B | 5.57 B | 4.53 B | 3.43 B | 5.69 B | 5.28 B | 5.46 B | 6.69 B | 4.41 B | 6.24 B | 3.8 B | 5.26 B | 2.79 B | 1.49 B | 1.49 B | 3.24 B | 4.67 B | 2.81 B | 4.2 B | 4.2 B | 4.15 B | 4.15 B | 5.28 B | 5.28 B | 3.09 B | 3.09 B | 2.49 B | 2.49 B | 1.67 B | 1.67 B |
Gross Profit Ratio |
0.331 | 0.339 | 0.337 | 0.233 | 0.21 | 0.18 | 0.164 | 0.258 | 0.234 | 0.213 | 0.295 | 0.19 | 0.275 | 0.241 | 0.327 | 0.263 | 0.251 | 0.251 | 0.709 | 0.845 | 0.476 | 0.412 | 0.412 | 0.394 | 0.394 | 0.344 | 0.344 | 0.298 | 0.298 | 0.347 | 0.347 | 0.386 | 0.386 |
General and Administrative Expenses |
278 M | 14 B | 266 M | - | 84 M | 4.74 B | 172 M | 546 M | 248 M | 8.05 B | 8.06 B | 97 M | 109 M | 185 M | 91 M | - | 157 M | 157 M | 3.26 B | 3.88 B | 1.99 B | 3.57 B | 3.57 B | 3.68 B | 3.68 B | 5.15 B | 5.15 B | 3.74 B | 3.74 B | - | - | - | - |
Selling And Marketing Expenses |
165 M | 113 M | 100 M | - | 47.5 M | 43 M | 71 M | 197 M | 96 M | 159 M | 70 M | 134 M | 54 M | 13 M | 65 M | - | 58.5 M | 58.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Selling General And Administrative Expenses |
4.79 B | 10.6 B | 3.85 B | 2.55 B | 4.79 B | 4.78 B | 4.29 B | 5.36 B | 4.2 B | 8.2 B | 8.13 B | 9.25 B | 5.32 B | 5.02 B | 3.93 B | 2.94 B | 216 M | 216 M | 3.26 B | 3.88 B | 1.99 B | 3.57 B | 3.57 B | 3.68 B | 3.68 B | 5.15 B | 5.15 B | 3.74 B | 3.74 B | 2.32 B | 2.32 B | 1.45 B | 1.45 B |
Other Expenses |
- | - | - | 3 M | -9 M | -14 M | -14 M | - | - | - | - | - | - | - | - | - | 5.18 B | 5.18 B | 44 M | - | 4 M | 7.6 M | 7.6 M | 242 M | 242 M | -15.1 M | -15.1 M | -43.6 M | -43.6 M | - | - | - | - |
Operating Expenses |
4.79 B | 10.6 B | 3.85 B | 2.54 B | 4.8 B | 4.8 B | 4.31 B | 19.6 B | 7.75 B | 14.1 B | 7.74 B | 12.2 B | 5.49 B | 4.56 B | 3.8 B | 2.61 B | 5.4 B | 5.4 B | 3.26 B | 3.88 B | 1.99 B | 3.57 B | 3.57 B | 3.68 B | 3.68 B | 5.14 B | 5.14 B | 3.77 B | 3.77 B | 2.32 B | 2.32 B | 1.45 B | 1.45 B |
Cost And Expenses |
25.2 B | 25.9 B | 17.7 B | 12.3 B | 25.7 B | 25.4 B | 21.7 B | 36 B | 25.1 B | 34.2 B | 23.7 B | 31.1 B | 21.9 B | 16.6 B | 14.6 B | 10.5 B | 9.86 B | 9.86 B | 9.16 B | 10.3 B | 5.08 B | 9.56 B | 9.56 B | 10.1 B | 10.1 B | 15.2 B | 15.2 B | 11.1 B | 11.1 B | -7.02 B | -7.02 B | -4.1 B | -4.1 B |
Interest Expense |
- | - | - | 2.1 B | 2.52 B | 2.83 B | 2.55 B | - | - | - | - | - | - | - | - | - | 739 M | 739 M | - | 776 M | - | 631 M | 631 M | 587 M | 587 M | 540 M | 540 M | 472 M | 472 M | 229 M | 229 M | 214 M | 214 M |
Depreciation And Amortization |
831 M | 517 M | 653 M | 2.5 B | 2.52 B | 2.63 B | 2.52 B | 531 M | 601 M | 801 M | 671 M | 763 M | 256 M | 184 M | 226 M | 74 M | 114 M | 114 M | 192 M | 218 M | 112 M | 238 M | 238 M | 240 M | 240 M | 317 M | 317 M | 250 M | 250 M | 176 M | 176 M | 110 M | 110 M |
EBITDA |
3.31 B | 968 M | 1.16 B | 2.93 B | 3.22 B | 175 M | 2.3 B | -1.78 B | -1.11 B | -2.77 B | -327 M | -4.88 B | 912 M | -1.28 B | 1.31 B | -73 M | -4.09 B | -4.09 B | 174 M | 1.29 B | 930 M | 869 M | 869 M | 905 M | 905 M | 237 M | 237 M | -424 M | -424 M | 1.11 B | 1.11 B | 516 M | 516 M |
EBITDA Ratio |
0.109 | 0.048 | 0.056 | 0.23 | 0.124 | 0.094 | 0.079 | -0.081 | -0.049 | -0.108 | -0.014 | -0.21 | 0.04 | -0.081 | 0.081 | -0.007 | -0.687 | -0.687 | 0.038 | 0.233 | 0.158 | 0.085 | 0.085 | 0.086 | 0.086 | 0.015 | 0.015 | -0.041 | -0.041 | 0.154 | 0.154 | 0.12 | 0.12 |
Operating Income |
5.3 B | -2.68 B | 3.18 B | 438 M | 768 M | -265 M | -877 M | -2.31 B | -1.71 B | -3.57 B | -998 M | -5.64 B | 656 M | -1.46 B | 1.08 B | -147 M | -3.9 B | -3.9 B | -18 M | 796 M | 818 M | 631 M | 631 M | 440 M | 440 M | -202 M | -202 M | -696 M | -696 M | 170 M | 170 M | 213 M | 213 M |
Operating Income Ratio |
0.174 | 0.011 | 0.152 | 0.034 | 0.029 | -0.011 | -0.042 | -0.105 | -0.076 | -0.139 | -0.044 | -0.243 | 0.029 | -0.093 | 0.067 | -0.014 | -0.655 | -0.655 | -0.004 | 0.144 | 0.139 | 0.062 | 0.062 | 0.042 | 0.042 | -0.013 | -0.013 | -0.067 | -0.067 | 0.024 | 0.024 | 0.049 | 0.049 |
Income Before Tax |
159 M | -186 M | -1.26 B | 1.5 B | -2.14 B | -5 B | -3.74 B | -17.3 B | -5.5 B | -10.7 B | -2.46 B | -9.33 B | -72 M | -1.68 B | 350 M | -402 M | -4.94 B | -4.94 B | -838 M | 294 M | 359 M | -19.6 M | -19.6 M | 77.4 M | 77.4 M | -885 M | -885 M | -1.25 B | -1.25 B | 701 M | 701 M | 192 M | 192 M |
Income Before Tax Ratio |
0.005 | -32.7 | -60.2 | 0.117 | -0.081 | -0.199 | -0.179 | -0.782 | -0.243 | -0.417 | -0.109 | -0.401 | -0.003 | -0.106 | 0.022 | -0.038 | -0.83 | -0.83 | -0.183 | 0.053 | 0.061 | -0.002 | -0.002 | 0.007 | 0.007 | -0.058 | -0.058 | -0.12 | -0.12 | 0.098 | 0.098 | 0.045 | 0.045 |
Income Tax Expense |
72 M | 457 M | 35 M | 107 M | 242 M | 85 M | 25 M | 203 M | 17 M | 63 M | 20 M | 51 M | 105 M | 28 M | 142 M | 3 M | 85 M | 85 M | 138 M | 290 M | 95 M | 197 M | 197 M | 64.6 M | 64.6 M | 191 M | 191 M | 115 M | 115 M | 133 M | 133 M | 63.8 M | 63.8 M |
Net Income Ratio |
0.003 | -0.022 | -0.062 | 0.019 | -0.09 | -0.202 | -0.18 | -0.792 | -0.244 | -0.415 | -0.109 | -0.403 | 0.001 | -0.028 | 0.016 | -0.037 | -0.873 | -0.873 | 0.008 | -0.076 | -0.082 | -0.046 | -0.046 | -0.017 | -0.017 | -0.054 | -0.054 | -0.144 | -0.144 | 0.065 | 0.065 | 0.027 | 0.027 |
Earnings Per Share, EPS |
0.011 | 0.05 | -0.17 | 0.032 | -0.35 | -0.74 | -1.21 | -7.5 | -2.36 | -4.56 | -1.06 | -8.92 | 0.034 | -0.46 | 0.28 | -3.8 | -41.2 | -41.2 | 0.26 | - | - | -3.88 | -3.88 | -0.037 | -0.037 | -0.17 | -0.17 | -0.3 | -0.3 | 51.8 | 51.8 | 13 | 13 |
EPS Diluted |
0.011 | 0.05 | -0.17 | 0.032 | -0.35 | -0.74 | -1.21 | -7.5 | -2.36 | -4.56 | -1.06 | -8.92 | 0.034 | -0.46 | 0.28 | -3.8 | -41.3 | -41.3 | 0.26 | - | - | -3.88 | -3.88 | -0.037 | -0.037 | -0.17 | -0.17 | -0.3 | -0.3 | 51.8 | 51.8 | 13 | 13 |
Weighted Average Shares Outstanding |
7.63 B | 7.63 B | 7.63 B | 7.63 B | 6.84 B | 6.84 B | 3.12 B | 2.33 B | 2.33 B | 2.33 B | 2.33 B | 1.05 B | 977 M | 969 M | 903 M | 104 M | 126 M | 126 M | 252 M | - | - | 120 M | 120 M | 4.88 B | 4.88 B | 4.88 B | 4.88 B | 4.88 B | 4.88 B | 9.05 M | 9.05 M | 9.05 M | 9.05 M |
All numbers in RUB currency
The income statement is one of the three key financial reports of a company Аптеки 36.6 (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Pharmaceutical retailers industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
China Jo-Jo Drugstores, Inc.
CJJD
|
- | -5.59 % | $ 49.9 M |  China |
 |
Greenlane Holdings
GNLN
|
$ 2.16 | -1.82 % | $ 16.3 M |  USA |
 |
BOQI International Medical
BIMI
|
- | 6.33 % | $ 5.86 M | China |
 |
Trxade Group
MEDS
|
- | 4.55 % | $ 5.8 M | USA |
 |
PetMed Express
PETS
|
$ 3.55 | 3.8 % | $ 73.1 M | USA |
 |
LifeMD
LFMD
|
$ 4.0 | 15.61 % | $ 136 M | USA |
 |
Rite Aid Corporation
RAD
|
- | - | $ 35.5 M | USA |
 |
111
YI
|
$ 3.09 | 3.62 % | $ 531 M | China |
 |
Walgreens Boots Alliance
WBA
|
- | - | $ 10.3 B | USA |